Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed · Phase 3 · NCT03088540
Conditions: Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $2,275
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 712
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Pemetrexed (drug), Paclitaxel (drug), Gemcitabine (drug), Cisplatin (drug), Carboplatin (drug), cemiplimab (drug)
- Dates
- Started 2017-05-29; completion 2025-04-18
- Results posted
- Yes
The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2,275 in research payments for this study in 2025 (6 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,275
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.